Ebos Group Ltd (ASX:EBO) is a healthcare and animal care distribution and retail group operating across Australia, New Zealand and Southeast Asia. Its Healthcare segment includes Symbion's community pharmacy distribution, hospital medicines, contract logistics, retail pharmacy brands such as TerryWhite Chemmart, and medical technology. Its Animal Care segment includes pet food brands such as Black Hawk and VitaPet. EBOS is listed on the NZX and ASX. Adam Hall is CEO.

On 2 October 2026, EBOS shares were trading at $15.14, down 1.88%. The group's full-year results, released in August, marked the completion of a four-year distribution centre renewal program.

EBOS has headquarters in Christchurch, New Zealand, and Melbourne, Australia. Its businesses Supply community pharmacies, hospitals, aged care and healthcare customers, and include contract logistics for pharmaceutical companies. Animal Care brands include Black Hawk, VitaPet and Lyppard.

Recent Developments

On 19 August 2026, EBOS reported its results for the year to 30 June 2026. Figures are in Australian dollars. Key points include:

  • Revenue increased 9.9% to $13.5 billion.
  • Gross operating Revenue rose 6.5% to $1.7 billion.
  • Underlying EBITDA increased 5.0% to $614 million.
  • Underlying NPAT was $250 million, down 3.1%, due to higher depreciation, Amortisation and financing costs.
  • Statutory NPAT was $225 million, up 4.7%.
  • Leverage was 2.1 times, within the 1.7 to 2.3 times target range.
  • The final Dividend was maintained at NZ 61.5 cents per share, a Payout Ratio of 84.5% of underlying NPAT.

Mr Hall said FY26 was an important year, with solid EBITDA growth and completion of the largest infrastructure Investment program in the group's history, the $360 million distribution centre renewal. Healthcare revenue grew 8.5% to $12.6 billion, with underlying EBITDA up 3.2% to $516 million, supported by community pharmacy, hospital medicines, medical technology and contract logistics, including Demand for GLP-1 and other high-value medicines. TerryWhite Chemmart network sales rose 9.2% to about $2.9 billion.

Animal Care revenue increased 34.6% to $907 million, with underlying EBITDA up 11.6% to $138 million, supported by the SVS Acquisition and growth in branded portfolios. EBOS acquired Paringa Pet Foods and K-Talyst, among others. For FY27, EBOS is targeting underlying EBITDA of $635 million to $655 million, with Capital Expenditure expected to fall to about $100 million. Depreciation and amortisation are expected to be $152 million to $162 million, and net finance costs $138 million to $148 million.

Community Pharmacy revenue rose 10.2% to $7.1 billion, and Contract Logistics GOR increased 13.1% to $174 million. Medical Technology revenue grew 5.5%, or 8.4% at constant currency, supported by four acquisitions. Total pharmacy network stores reached 780, up 86, including MediAdvice. EBOS deployed about $400 million across capex, M&A and Shareholder returns in FY26. Chair Elizabeth Coutts said the board remains confident in the group's diversified Earnings base. The final dividend has a Record Date of 28 August 2026 and payment date of 18 September 2026, and is fully franked for Australian tax residents.

Sector Context

Pharmaceutical wholesale and distribution businesses operate on thin margins, earning income from Volume and services. Demand is supported by an ageing population and growth in high-value medicines such as GLP-1 drugs, but product mix can affect margins. Government funding arrangements, such as the Community Service Obligation in Australia, influence profitability.

Retail pharmacy networks are expanding health services, including vaccinations and consultations. Animal care has become a growth area, with pet owners spending more on premium nutrition and veterinary products. Logistics efficiency and distribution infrastructure are key competitive factors.

GLP-1 medicines, used for diabetes and weight management, have driven significant growth in pharmacy sales but can affect distributor margins due to their high value. Distributors with modern warehouses and automation may benefit from productivity improvements.

In Australia, the Community Service Obligation funding arrangement supports pharmaceutical wholesalers that deliver medicines to pharmacies across the country, including remote areas. Changes to this funding can significantly affect wholesaler profitability. The premium pet food market has grown as owners spend more on nutrition, supporting companies with branded and fresh or chilled products.

Risks and Uncertainties

EBOS' underlying NPAT declined due to higher depreciation and finance costs, which are expected to rise further in FY27. Competition in wholesale pharmacy and Margin pressure from product mix could affect earnings. Fuel and energy costs affected FY26 results. Integration of acquisitions carries execution risk. Currency movements between the Australian and New Zealand dollars affect reported results and dividends.

Earnings and cash flows are weighted to the second half, which can create variability in half-year results.

The Healthcare segment's EBITDA margin declined slightly, and further product mix shifts toward high-value, lower-margin medicines could continue this trend.

Catalysts Investors Can Watch

Investors may watch for productivity gains from the new distribution centres, including Kemps Creek, progress toward FY27 EBITDA guidance, the effect of CSO funding reforms, and growth in Animal Care and Medical Technology. Leverage trends will also be relevant.

Updates on retail pharmacy brands, including owned Brand growth and health services, may also be followed.

The Bottom Line

EBOS's FY26 result showed revenue and EBITDA growth with its distribution centre program now complete. Lower capital intensity and network productivity are expected to be key themes in FY27.

Its diversified portfolio across healthcare and animal care provides multiple sources of earnings.